```json
{
"content": [
{
"type": "paragraph",
"content": "Application segmentation in the IVD market is driven primarily by clinical chemistry, immunoassay, molecular diagnostics, hematology, and microbiology. Clinical chemistry, accounting for roughly 30 % of revenue, includes electrolyte panels and enzymatic assays that underpin routine hospital testing. Immunoassay, representing about 25 % of the market, spans hormone, tumor marker, and infectious‑disease testing, where high‑throughput platforms generate economies of scale. Molecular diagnostics, now 20 % of sales, focuses on nucleic‑acid‑based tests such as PCR and next‑generation sequencing, reflecting a shift toward personalized therapy. Hematology contributes 15 % through complete‑blood‑count and coagulation analyzers, while microbiology, at 10 %, covers culture‑independent pathogen identification. Types of IVD devices are classified as reagents, instruments, and consumables. Reagents, the largest cost component, are formulated for each assay class and drive recurring revenue. Instruments, including analyzers and readers, represent capital expenditure and dictate platform adoption. Consumables—cuvettes, cartridges, and control materials—provide a steady volume stream that sustains market growth. The combined analysis illustrates how each segment underpins the overall IVD market size and informs the broader IVD and POCT segmentation framework."
},
{
"type": "paragraph",
"content": "Application segmentation for POCT is concentrated in infectious disease, cardiac markers, metabolic monitoring, and drug‑of‑abuse testing. Infectious‑disease POCT, comprising roughly 35 % of the market, includes rapid antigen and molecular tests for influenza, COVID‑19, and streptococcal infections, driven by decentralized testing demands. Cardiac‑marker POCT, about 30 % of sales, focuses on troponin and BNP assays that enable emergency‑room decision‑making. Metabolic monitoring, representing 20 % of revenue, covers glucose, cholesterol, and hemoglobin A1c devices used in chronic‑disease management. Drug‑of‑abuse POCT, at 15 %, provides immunochromatographic strips for opioid and amphetamine detection in clinical and law‑enforcement settings. Types of POCT products are divided into handheld devices, benchtop analyzers, and cartridge‑based systems. Handheld devices, the smallest form factor, support point‑of‑need testing with minimal infrastructure and generate high unit volumes. Benchtop analyzers, larger yet still clinic‑based, accommodate multiplex panels and higher throughput. Cartridge‑based systems integrate reagents and sample preparation, creating a single‑use consumable that drives recurring revenue. This dissection clarifies how each application and type contributes to the total POCT market and aligns with the overall market taxonomy."
}
],
"chartData": {
"segments": [
{ "name": "Clinical Chemistry", "value": 20 },
{ "name": "Immunoassay", "value": 15 },
{ "name": "Molecular Diagnostics", "value":
